Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston TX YC W20 clinical-stage AV fistula wrap for dialysis patients with 200-patient RCT underway; $22.8M total ($20M Good Growth/Norwest Series A Jun 2024 + $3.6M NIH grant) targeting vascular access failure competing for dialysis market.
VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.
Kindful, nonprofit donor management/CRM platform (acquired by Bloomerang 2020), 1,000+ nonprofit customers, cloud-based fundraising software, online donation forms, donor analytics, email marketing, integrated with QuickBooks/Mailchimp, now part of Bloomerang suite
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid-sized nonprofits who need affordable, user-friendly software to organize donor data, process contributions, and measure fundraising effectiveness. Kindful provides tools for online giving, email marketing, event management, donor segmentation, and reporting that help nonprofits build stronger relationships with supporters, streamline fundraising operations, and increase donations while reducing administrative burden.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.